Your session is about to expire
← Back to Search
Study Summary
This trial studies the safety and effectiveness of an antibody, GEN1047, in treating cancer. Participants will get GEN1047 in two parts to assess safety, dose and preliminary activity.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had a bowel blockage due to my illness.I am a woman and at least 18 years old or the legal age of consent.I can provide all CT scans since my last treatment didn't work.My cancer is advanced or has spread, and this was confirmed by a lab test.I am at least 18 years old or the legal age of consent where the trial is.I am fully active or restricted in physically strenuous activity but can do light work.I can provide a sample of my tumor before starting the trial.I have new or worsening brain tumors or spinal cord compression.My solid tumor cancer has no other standard treatments likely to help.I have at least one tumor that can be measured and was not treated with radiation.I have previously been treated with therapies targeting CD3/B7H4 or received cell-based treatments.I can provide a sample of my tumor before starting the trial.My cancer has returned or didn't respond to standard treatments, or I can't tolerate them.My ovarian cancer has worsened after my last treatment, within the past 60 days.I am fully active or restricted in physically strenuous activity but can do light work.I have not had major heart problems in the last 6 months.I have or had lung inflammation not caused by an infection that needed steroids.I can provide all CT scans since my last treatment didn't work.My latest scan shows my cancer has progressed despite treatment, and was done within the last 28 days.You must have at least one spot that can be measured by your doctor.
- Group 1: GEN1047
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this particular trial actively seeking participants?
"According to clinicaltrials.gov, the search for participants is still ongoing - this trial was initially advertised on December 13th 2021 and has been regularly updated ever since its inception on April 19th 2023."
What is the participant count of this experiment?
"Affirmative. Clinicaltrials.gov data confirms that this research project, which was originally posted on December 13th 2021 is actively recruiting participants. Five hundred patients need to be enrolled at 8 different medical centres."
How many research sites are undertaking this trial?
"8 clinical sites, located in Nashville, Pamplona and Paris amongst other cities, are running this trial. When considering participation, it is best to select the nearest location so as to reduce travel time."
Share this study with friends
Copy Link
Messenger